Development and validation of risk models and molecular diagnostics to permit personalized management of cancer

Cancer. 2014 Jan 1;120(1):11-9. doi: 10.1002/cncr.28393. Epub 2013 Oct 2.

Abstract

Despite the advances made in cancer management over the past few decades, improvements in cancer diagnosis and prognosis are still poor, highlighting the need for individualized strategies. Toward this goal, risk prediction models and molecular diagnostic tools have been developed, tailoring each step of risk assessment from diagnosis to treatment and clinical outcomes based on the individual's clinical, epidemiological, and molecular profiles. These approaches hold increasing promise for delivering a new paradigm to maximize the efficiency of cancer surveillance and efficacy of treatment. However, they require stringent study design, methodology development, comprehensive assessment of biomarkers and risk factors, and extensive validation to ensure their overall usefulness for clinical translation. In the current study, the authors conducted a systematic review using breast cancer as an example and provide general guidelines for risk prediction models and molecular diagnostic tools, including development, assessment, and validation.

Keywords: cancer; model assessment; molecular diagnosis; personalized management; risk prediction model.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Humans
  • Models, Statistical*
  • Neoplasms / diagnosis*
  • Neoplasms / genetics
  • Neoplasms / therapy*
  • Pathology, Molecular
  • Precision Medicine / methods*
  • Prognosis
  • Proportional Hazards Models
  • Reproducibility of Results
  • Risk Assessment
  • Risk Factors